CMS Drafts Rules to Slash Medicare Drug Prices Soon
Published Date: 5/15/2025
Notice
Summary
CMS is inviting everyone to share their thoughts on new rules for negotiating drug prices under Medicare starting in 2026. This affects drug makers and Medicare patients by aiming to lower medicine costs through fair price limits. The changes kick in over the next few years, helping save money and making medicines more affordable.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Medicare drug prices capped 2026–2028
You (Medicare patients) are affected by new Medicare Drug Price Negotiation Program rules that set a "maximum fair price" for certain medicines for 2026, 2027, and 2028. CMS says the changes aim to lower medicine costs and make medicines more affordable, and CMS is seeking public comment on draft guidance for those years.
Manufacturers must effectuate fair prices
If you are a drug manufacturer, CMS' draft guidance covers manufacturer effectuation of the "maximum fair price" and negotiation cycles for drugs for 2026, 2027, and 2028. The guidance applies to drug makers as CMS implements the Inflation Reduction Act negotiation and renegotiation process for those years.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in